NDAORALTABLET, ORALLY DISINTEGRATING
Approved
Jun 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZELAPAR is an orally disintegrating tablet formulation of selegiline hydrochloride, an irreversible monoamine oxidase type B (MAO-B) inhibitor approved for adjunctive treatment in Parkinson's disease and cognitive disorders. It works by selectively inhibiting MAO-B in the brain, preserving dopamine and potentially increasing dopaminergic activity through multiple mechanisms including dopamine reuptake interference.
$0.626MPart D
LOE ApproachingZELAPAR is approaching loss of exclusivity with minimal Part D penetration ($626K, 110 claims in 2023), suggesting a niche product with declining commercial team investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ZELAPAR carries minimal career opportunity signals with zero linked job openings and approaching loss of exclusivity, indicating a small, stable team focused on maintenance and generic transition planning. Positions on this product are typically limited to contract-based commercial roles or specialty pharma organizations.
Company
Worked on ZELAPAR at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.